Streetbeat News

Regulatory

MBOT

Microbot Medical Inc. (NASDAQ:MBOT) has received a Grant of Protection from the Japan Patent Office for a Design Patent covering the robotic drive of the LIBERTY Robotic Surgical System. This expands the company's global IP portfolio, which includes 19 issued/allowed patents and 41 pending applications.

Portfolio Pulse from Happy Mohamed

June 22, 2023 | 12:43 pm

GILD

Kite Pharma, a Gilead Company, has announced the completion of the Marketing Authorization transfer for Yescarta CAR T-cell therapy in Japan from Daiichi Sankyo to Gilead Sciences K.K. The Kite Cell Therapy Business Unit of Gilead Sciences K.K. will now manage the sales and promotion activities of Yescarta in Japan.

Portfolio Pulse from Happy Mohamed

June 22, 2023 | 12:38 pm

KYMR

Kymera Therapeutics has received FDA Orphan Drug Designation for its MDM2 degrader, KT-253, for the treatment of acute myeloid leukemia.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 12:35 pm

ROP

Roper Technologies has announced its decision to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:32 pm

CENN

Cenntro Electric Group has received an extension from Nasdaq to regain compliance with the minimum bid price rule. The company now has until August 9, 2022, to meet the requirement.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:31 pm

AYRO

Electric vehicle manufacturer AYRO has submitted its new electric vehicle, Vanish, for testing.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:18 pm

F

Ford and SK Innovation's joint venture, BlueOvalSK, is set to receive a $9.2 billion government loan for battery plants in Kentucky and Tennessee, according to the Energy Department.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:17 pm

SEE

Seelos Therapeutics has closed enrollment for its registration-directed study of SLS-002, a treatment for acute suicidal ideation and behavior in adults with major depressive disorder.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 12:09 pm

BMRN

BioMarin Pharmaceutical (BMRN) will present data from the longest and largest hemophilia gene therapy clinical trial program, ROCTAVIAN, at the International Society on Thrombosis and Haemostasis 2023 Congress.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:05 pm

HZNP

Horizon Therapeutics reports positive topline data from Phase 3 clinical trial (OPTIC-J) in Japan for TEPEZZA (teprotumumab-trbw) in treating active thyroid eye disease (TED). At week 24, 89% of patients treated with TEPEZZA showed clinically meaningful improvement compared to 11% receiving placebo.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:05 pm